the most used cryptocurrency Top Knowledge graph

China Overseas Development: The annual interest of "23 Zhonghai 04" will be paid on December 12th. On December 10th, China Overseas Development (00688.HK) announced that China Overseas Enterprise Development Group Co., Ltd., a wholly-owned subsidiary of the company, will pay the annual interest of "23 Zhonghai 04" on December 12th, totaling 96 million yuan. The total amount of bonds issued in this issue is 3 billion yuan, and the issuance period is 5 years. The coupon rate of bonds in this issue is 3.20%.The cumulative delivery of Tucki P7+ has exceeded 10,000 units. On December 11th, Xpeng Motors announced that the cumulative delivery of Tucki P7+ has exceeded 10,000 units. He Xiaopeng, CEO of Xpeng Motors, appeared at the Guangzhou Delivery Center to deliver the 10,000th P7+ car owner, and He Xiaopeng revealed at the scene that Tucki P7+ had completed the third capacity increase.Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.

Academician Qiao Jie, Executive Vice President of Peking University, and his party visited Sunflower Pharmaceutical Group. On December 9th, Academician Qiao Jie, Executive Vice President of Peking University, and his party visited the headquarters of Sunflower Pharmaceutical Group for investigation and exchange. At the symposium, Tan Lei, general manager of the strategic management department of Sunflower Pharmaceutical Group, gave a detailed report on the promotion plan of the project "Peking University Medical-Sunflower Pharmaceutical Group Joint Laboratory of Bacterial Enzyme and Innovative Drugs". Sunflower Pharmaceutical Group will join hands with Peking University Medical Center, and the teams of the two sides will cooperate in depth to jointly develop new drugs based on the active substances of traditional Chinese medicine and the discovered important disease targets, promote the transformation of scientific research achievements, deepen the advantageous fields of biotechnology, and help improve the scientific research and innovation ability and technology development level. During the talks, the two sides also conducted in-depth exchanges and discussions on a number of contents.Academician Qiao Jie, Executive Vice President of Peking University, and his party visited Sunflower Pharmaceutical Group. On December 9th, Academician Qiao Jie, Executive Vice President of Peking University, and his party visited the headquarters of Sunflower Pharmaceutical Group for investigation and exchange. At the symposium, Tan Lei, general manager of the strategic management department of Sunflower Pharmaceutical Group, gave a detailed report on the promotion plan of the project "Peking University Medical-Sunflower Pharmaceutical Group Joint Laboratory of Bacterial Enzyme and Innovative Drugs". Sunflower Pharmaceutical Group will join hands with Peking University Medical Center, and the teams of the two sides will cooperate in depth to jointly develop new drugs based on the active substances of traditional Chinese medicine and the discovered important disease targets, promote the transformation of scientific research achievements, deepen the advantageous fields of biotechnology, and help improve the scientific research and innovation ability and technology development level. During the talks, the two sides also conducted in-depth exchanges and discussions on a number of contents.President of Japan Life Insurance: I don't think we are behind our competitors in overseas acquisitions, but we are concerned about different countries.

Can TCL make a three-fold mobile phone? Li Dongsheng responded: We have the technology, depending on the needs of the market. At the TCL Global Technology Innovation Conference held today, Li Dongsheng, the founder and chairman of TCL, attended the conference for the 11th time and made a live speech. At this conference, TCL exhibited and introduced the first Tandem three-fold screen (7.85 ") developed by the company. The folding screen can support "G-shaped" or "Z-shaped" folding, and combines Tandem, LTPO and PLP multiple low-power technologies to realize comprehensive promotion of high brightness, low power consumption and long service life. Will TCL launch three-fold mobile phones and other products? In the communication with Sina Technology, Li Dongsheng responded that "we have such technology", but we need to "see the market needs" whether to launch related products. (Sina Technology)Sony Group's share price hit a record high in intraday trading, and Sony Group's share price broke through the high of 3,390 yen set in 2000, reaching a record high.There is a wave of "restriction on purchases" in the public offering market. The announcement of Huitianfu Fund on December 11th shows that since December 12th, Huitianfu Enhanced Income Bond A has suspended large-scale subscription, large-scale conversion and large-scale fixed investment business, and the amount of single or multiple cumulative subscriptions, conversion and fixed investment in a single fund account per day should not exceed 10 million yuan (inclusive). Recently, the reporter found that there is a "restricted purchase tide" in the public offering market. Whether it is active equity funds, bond funds or QDII funds, many outstanding products have recently announced the suspension of large-scale subscription, and even QDII products have directly "closed the market" and suspended all buying operations. (CSI)